BG64680B1 - Химерен протеин на интерлевкин-6 разтворим рецептор/ лиганд, негови аналози и тяхното използване - Google Patents

Химерен протеин на интерлевкин-6 разтворим рецептор/ лиганд, негови аналози и тяхното използване Download PDF

Info

Publication number
BG64680B1
BG64680B1 BG104070A BG10407000A BG64680B1 BG 64680 B1 BG64680 B1 BG 64680B1 BG 104070 A BG104070 A BG 104070A BG 10407000 A BG10407000 A BG 10407000A BG 64680 B1 BG64680 B1 BG 64680B1
Authority
BG
Bulgaria
Prior art keywords
sil
protein
chimeric
cells
analogs
Prior art date
Application number
BG104070A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG104070A (en
Inventor
Michel Revel
Judith Chebath
Tsvee Lapidot
Orit Kollet
Original Assignee
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26323470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG64680(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IL12128497A external-priority patent/IL121284A0/xx
Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.
Publication of BG104070A publication Critical patent/BG104070A/xx
Publication of BG64680B1 publication Critical patent/BG64680B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BG104070A 1997-07-10 2000-01-10 Химерен протеин на интерлевкин-6 разтворим рецептор/ лиганд, негови аналози и тяхното използване BG64680B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12128497A IL121284A0 (en) 1997-07-10 1997-07-10 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
IL12281897A IL122818A0 (en) 1997-07-10 1997-12-30 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof

Publications (2)

Publication Number Publication Date
BG104070A BG104070A (en) 2000-11-30
BG64680B1 true BG64680B1 (bg) 2005-11-30

Family

ID=26323470

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104070A BG64680B1 (bg) 1997-07-10 2000-01-10 Химерен протеин на интерлевкин-6 разтворим рецептор/ лиганд, негови аналози и тяхното използване

Country Status (27)

Country Link
US (2) US7198781B1 (pt)
EP (1) EP0991661B1 (pt)
JP (1) JP4402288B2 (pt)
KR (1) KR100505172B1 (pt)
CN (1) CN1185348C (pt)
AR (1) AR013201A1 (pt)
AT (1) ATE342915T1 (pt)
AU (1) AU758161B2 (pt)
BG (1) BG64680B1 (pt)
BR (1) BR9812096B1 (pt)
CA (1) CA2295936C (pt)
CY (1) CY1105895T1 (pt)
CZ (1) CZ302488B6 (pt)
DE (1) DE69836217T2 (pt)
DK (1) DK0991661T3 (pt)
EA (1) EA004793B1 (pt)
EE (1) EE05519B1 (pt)
ES (1) ES2271999T3 (pt)
HK (1) HK1031895A1 (pt)
HU (1) HU225855B1 (pt)
IL (2) IL122818A0 (pt)
NO (1) NO327397B1 (pt)
NZ (1) NZ502139A (pt)
PL (1) PL199212B1 (pt)
PT (1) PT991661E (pt)
SK (1) SK287039B6 (pt)
WO (1) WO1999002552A2 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
US5919763A (en) * 1998-06-01 1999-07-06 Hadasit Medical Research Services And Development Company Ltd. IL-6/SIL-6R complex for promotion of liver functions
WO2000001731A1 (fr) * 1998-07-06 2000-01-13 Tosoh Corporation Proteine fusionnee avec liaison directe du recepteur il-6 a il-6
US20040170604A1 (en) 1998-07-06 2004-09-02 Tosoh Corporation IL-6 receptor IL-6 direct fusion protein
UA84387C2 (ru) * 1999-03-09 2008-10-27 Займодженетикс, Инк. Человеческий цитокин как лиганд зальфа рецептора и его применение
IL130586A0 (en) 1999-06-21 2000-06-01 Yeda Res & Dev IL6RIL6 chimera for the treatment of demyelinating diseases
EP1290170A2 (en) * 2000-06-16 2003-03-12 Asterion Limited Binding agents: chimeric ligand/receptor proteins
DK1317273T3 (da) * 2000-09-14 2006-09-04 Ares Trading Sa Anvendelse af IL-6R/IL-6-kimærer mod Huntingtons sygdom
DE10106827A1 (de) * 2001-02-14 2002-09-05 Stefan Rose-John Verwendung eines Konjugats aus Interleukin-6(IL-6) und seinem Rezeptor zur Induktion der zellulären Expression des Stammzellfaktors (SCF) und von Flat-3-Ligand (Flt-3L)
DE10107737A1 (de) * 2001-02-16 2002-09-05 S Rose John Christian Albrecht Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
GB0119015D0 (en) * 2001-08-03 2001-09-26 Univ Cardiff A fusion protein
GB2389115B (en) * 2001-12-14 2005-03-16 Asterion Ltd Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone
IL147412A0 (en) 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
AU2003223089A1 (en) * 2002-04-29 2003-11-17 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
FR2850621B1 (fr) * 2003-02-04 2006-12-08 Journee Paul Connecteur reliant un bras d'essuie-glace a un balai d'essuyage, qui comporte deux languettes pour le verrouillage transversal de bras d'essuie-glace
DE10321317A1 (de) * 2003-05-13 2004-12-23 Christian-Albrechts-Universität Zu Kiel Verfahren zum Nachweis des funktionellen IL-6/ sIL-6-Rezeptor-Komplexes und Test-Kit zur Durchführung dieses Verfahrens
IL157309A0 (en) * 2003-08-07 2004-02-19 Applied Research Systems Method for the purification of a non-immunoglobulin protein
IL159558A0 (en) 2003-12-24 2004-06-01 Applied Research Systems Use of il-6 in liver injury
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
EP3354723B1 (en) 2005-08-29 2023-12-13 Technion Research & Development Foundation Ltd. Media for culturing stem cells
AU2012261726B2 (en) * 2005-08-29 2015-03-12 Technion Research & Development Foundation Ltd. Media for Culturing Stem Cells
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
WO2008011081A2 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania Wsx-1/p28 as a target for anti-inflammatory responses
EP2733203B1 (en) 2006-08-02 2018-10-10 Technion Research & Development Foundation Ltd. Methods of expanding embryonic stem cells in a suspension culture
US20090098529A1 (en) * 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
JP5213075B2 (ja) 2007-06-15 2013-06-19 ジェネラックス・コーポレイション 腫瘍の画像化および／または処置のための微生物
GB0715216D0 (en) * 2007-08-03 2007-09-12 Asterion Ltd Leptin
CN101827857A (zh) * 2007-08-03 2010-09-08 埃斯特瑞恩有限公司 粒细胞集落刺激因子
EP2310508A1 (en) * 2008-07-02 2011-04-20 Emergent Product Development Seattle, LLC Tgf-b antagonist multi-target binding proteins
JP2012531885A (ja) * 2008-07-02 2012-12-13 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｉｌ６免疫治療剤
AU2010205782A1 (en) 2009-01-16 2011-09-08 Agirx Limited Vaccine compositions
ES2779048T3 (es) 2009-11-12 2020-08-13 Technion Res & Dev Foundation Medios de cultivo, cultivos celulares y métodos de cultivo de células madre pluripotentes en un estado indiferenciado
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
SG10201800628QA (en) 2010-09-07 2018-02-27 Technion Res & Dev Foundation Novel Methods And Culture Media For Culturing Pluripotent Stem Cells
EP2832856A4 (en) 2012-03-29 2016-01-27 Chugai Pharmaceutical Co Ltd ANTI-LAMP5 ANTIBODIES AND USE THEREOF
KR20150145260A (ko) 2013-04-19 2015-12-29 싸이튠 파마 감소된 혈관 누출 증후근에 대한 사이토카인 유도체 치료
EP3033415A4 (en) * 2013-08-12 2017-01-11 Merck Sharp & Dohme Corp. Methods and compositions for co-expression of polypeptides of interest and il6
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
CN104826093A (zh) * 2015-04-16 2015-08-12 刘永庆 用于治疗慢性传染性肝病的Th2免疫反应拮抗剂及卵黄抗体
CN104922659B (zh) * 2015-07-03 2018-04-20 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
WO2022256688A1 (en) 2021-06-04 2022-12-08 Sonnet BioTherapeutics, Inc. Methods of treating age-related frailty with interleukin-6

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216128A (en) 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
IL99803A (en) * 1991-10-20 1997-02-18 Yeda Res & Dev Pharmaceutical compositions comprising interleukin-6 for the treatment of chronic lymphocytic leukemia and B-cell lymphomas
PL190445B1 (pl) * 1995-05-15 2005-12-30 Akademia Medyczna Im K Marcink Genetyczna szczepionka przeciwrakowa
DE19608813C2 (de) 1996-03-07 1998-07-02 Angewandte Gentechnologie Syst Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
IL136855A0 (en) * 1997-12-19 2001-06-14 Applied Research Systems Ifnar2/ifn complex

Also Published As

Publication number Publication date
ES2271999T3 (es) 2007-04-16
PL199212B1 (pl) 2008-08-29
JP4402288B2 (ja) 2010-01-20
CZ200075A3 (cs) 2000-08-16
SK287039B6 (sk) 2009-10-07
CN1269835A (zh) 2000-10-11
EP0991661B1 (en) 2006-10-18
HUP0002426A2 (hu) 2000-11-28
HU225855B1 (en) 2007-11-28
SK62000A3 (en) 2000-07-11
CZ302488B6 (cs) 2011-06-15
CA2295936A1 (en) 1999-01-21
NO20000086L (no) 2000-03-08
JP2001509371A (ja) 2001-07-24
KR100505172B1 (ko) 2005-08-03
AR013201A1 (es) 2000-12-13
BR9812096B1 (pt) 2011-09-06
CY1105895T1 (el) 2011-02-02
AU758161B2 (en) 2003-03-20
NZ502139A (en) 2002-03-28
CN1185348C (zh) 2005-01-19
WO1999002552A3 (en) 1999-04-01
AU8127198A (en) 1999-02-08
HUP0002426A3 (en) 2003-01-28
NO20000086D0 (no) 2000-01-07
BR9812096A (pt) 2000-07-18
EE05519B1 (et) 2012-02-15
CA2295936C (en) 2009-05-26
DE69836217T2 (de) 2007-08-23
EA200000109A1 (ru) 2000-08-28
US7374912B2 (en) 2008-05-20
HK1031895A1 (en) 2001-06-29
EP0991661A2 (en) 2000-04-12
NO327397B1 (no) 2009-06-22
KR20010021522A (ko) 2001-03-15
US7198781B1 (en) 2007-04-03
BG104070A (en) 2000-11-30
ATE342915T1 (de) 2006-11-15
US20070172455A1 (en) 2007-07-26
DE69836217D1 (de) 2006-11-30
IL133972A (en) 2015-07-30
EA004793B1 (ru) 2004-08-26
PL338002A1 (en) 2000-09-25
IL122818A0 (en) 1998-08-16
DK0991661T3 (da) 2007-02-05
WO1999002552A2 (en) 1999-01-21
EE200000012A (et) 2000-08-15
PT991661E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
BG64680B1 (bg) Химерен протеин на интерлевкин-6 разтворим рецептор/ лиганд, негови аналози и тяхното използване
ES2240981T3 (es) Citocina denominada lerk-7.
ES2253753T3 (es) Citocina que induce apoptosis.
KR100320106B1 (ko) 트롬보포이에틴폴리펩티드분비방법
US8163520B2 (en) Nucleic acids encoding a chimeric polypeptide comprising IL-7 and HGF-beta chain and methods of use
ES2287773T3 (es) Composiciones y metodos relacionados con fragmentos solubles multimericos y oligomericos del receptor tweak.
AU4027799A (en) Osteoporosis treatment
EP1148065B1 (en) Fusion proteins comprising two soluble gp130 molecules
NZ238659A (en) Mast cell growth factor, recombinant production and isolated sequences
NZ501831A (en) Trail binding protein (TRAIL-BP) showing significant homology to the extracellular domains of members of the tumour necrosis factor receptor (TNF-R) and is anchored to cell surface via glycosylphosphatidylinositol (GPI) linkage
KR20000029998A (ko) 발현벡터,세포,그리고혈소판조혈인자를제조하는방법
MXPA00000364A (en) Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof
CA2224625A1 (en) P-selectin ligands and related molecules and methods
MXPA97004173A (en) Designated citoquina lce
MXPA97010399A (es) Citocina que induce apoptosis